A board investigation found executives at Alexion Pharmaceuticals inappropriately encouraged staff to pressure customers into ordering its drug Soliris earlier than necessary to boost sales, reports ...

Alexion Pharmaceuticals will pay a huge premium to buy Synageva BioPharma in an $8.4-billion deal for a rare disease treatment maker that lost nearly $60 million in the first quarter and has no ...

Alexion Pharmaceuticals agreed to pay $13 million to settle allegations that it used charities to pay kickbacks to Medicare patients, according to a STAT news report. The settlement, disclosed in a ...

On June 11, 2025, the Delaware Court of Chancery found Alexion Pharmaceuticals liable for more than $180 million in damages to former stockholders of Syntimmune, Inc., following the Court’s September ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is the leading drugmaker in the treatment of cystic fibrosis, a life-threatening genetic disease that causes infections to several organs, including the lungs and ...

Alexion Pharmaceuticals v Amgen (UPC_Coa-405/2024) and Alexion Pharmaceuticals v Samsung Bioepis NL BV (UPC_CoA-402/2024); December 20, 2024. The UPC Court of Appeal has confirmed a strict approach to ...

JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, has achieved a key research milestone in ...

New Haven-based Alexion Pharmaceuticals Inc. today announced that it has reached a national funding agreement that provides access to enzyme replacement therapy for patients in England with an ...

The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris MISSISSAUGA, ON, Aug. 7, 2025 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's ...